Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1841-1845

  Vici, Patrizia ^a   Giotta, Francesco ^b   Di Lauro, Luigi ^a   Brandi, Mario ^b   Gebbia, Vittorio ^c   Foggi, Paolo ^a   Lorusso, Vito ^d   Vitucci, Carlo ^a   Sergi, Domenico ^a   Fattoruso, Silvia Ileana ^a   Giannarelli, Diana ^a   Viola, Giuditta ^a   Corsetti, Serena ^a   Colucci, Giuseppe ^b   Lopez, Massimo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

^d VITO FAZZI HOSPITAL   (Italy)

Author keywords

Advanced breast cancer; Docetaxel; Gemcitabine

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; GEMCITABINE;

ARTICLE; BONE LESION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTESTINE INJURY; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE; TREATMENT RESPONSE; VOMITING;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; TAXOIDS;

EID: 67650079724     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gralow J: Optimising the treatment of metastatic breast cancer. Breast Cancer Res Treat 89: 9-15, 2005.
2. Lyseng-Williamson KA and Fenton C: Docetaxel: a review of it use in metastatic breast cancer. Drags 65: 2513-2531, 2005. (Pubitemid 41697318)
3. Seidman AD: The evolving role of gemcitabine in the management of breast cancer. Oncology 60: 189-198, 2001. (Pubitemid 32424523)
4. Zoli W, Ricotti L, Dal Susino M, Barzanti F, Frassineti GL, Folli S, Tesei A, Bacci F and Amadori D: Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 81: 609-615, 1999. (Pubitemid 29458855)
5. Ishmael DR, Hamilton SA, Launey-Rodolf RM, Nordquist J and Nordquist RE: Phase VII of sequential docetaxel and gemcitabine: A new schedule based on preclinical testing with the BOT-2 human breast cancer cell line. Proc Am Soc Clin Oncol 20: 119a (abstract 473), 2001.
6. Ricotti L, Tesei A, De Paola F, Ulivi P, Frassineti GL, Milandri C, Amadori D and Zoli W: In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9: 900-905, 2003.
7. Rigas JR, Rothenburg ML, Davis TH, Mayrer LH, Perez R, Meyer L, Smith E, Elshamy M, Browning R, Harris L and Hammond S: A phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules. Proc Am Soc Clin Oncol 18: 226a (abstract 870), 1999.
8. Denes AE, Needles BM, Schmidt A, White LA, Greco AO and Eckardt JR: A comparison of two schedules of docetaxel (D) in combination with gemcitabine (G) given every other week. Proc Am Soc Clin Oncol 19: 212a (abstract 828), 2000.
9. Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonicolis J, Kakolyris S, Samonis G and Georgoulias V: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10: 211-215, 1999. (Pubitemid 29113182)
10. Fountzilas G, Nicolaides C, Bafaloukos D, Kalogera-Fountzila A, Kalofonos H, Samelis G, Aravantinos G and Pavlidis N: Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18: 503-509, 2000. (Pubitemid 30485665)
11. Brandi M, Giotta F, Vici P, Valerio MR, Vinciarelli G, Gebbia V, Galetta D, Lopez M and Colucci G: Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC): Preliminary results of a multicenter phase trial of GOIM (Grappo Oncologico dell'Italia Meridionale). Proc Am Soc Clin Oncol 20: 52b (abstract 1956), 2001.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 215-216, 2000.
13. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), ver.3.0: http://ctep.cancer.gov/reporting/ctc.htlm.
14. Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N, Schittulli F and Colucci G: Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31: 13-19, 2004. (Pubitemid 38658229)
15. Azambuja E, Durbecq V, Rosa D, Colozza M, Larsimont D, Piccart-Gebhart M and Cardoso F: HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19: 113-131, 2008. (Pubitemid 351201701)
16. Kornek GV, Haider K, Kwasny W, Raderer M, Schüll B, Payrits T, Depisch D, Kovats E, Lang F and Scheithauer W: Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8: 1051-1056, 2002. (Pubitemid 34517639)
17. Mavroudis D, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G and Georgoulias V; Breast Cancer Study Group of the Hellenic Oncology Research Group: Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology 67: 250-256, 2004.
18. Pelegrí A, Calvo L, Antón A, Mayordomo JI, Florián J, Vásquez S, Arcusa A, Martín-Richard M, Bayo JL, Carrasco E and Virizuela J; Spanish Group for Breast Cancer Research: Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. Clin Breast Cancer 6: 433-438, 2005.
19. O'Shaughnessy JA, Pluenneke R, Sternberg J, Khandelwal P, Ilegbodu D and Asmar L: Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 6: 505-510, 2006.
20. Chan S, Romieu G, Huober J, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Carrasco E, Thareau Vaury A and Fumoleau P: Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results. Breast Cancer Res Treat 106(S1): 68 (abstract 1078), 2007.
21. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S and Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20: 2812-2823, 2002. (Pubitemid 34651510)
22. Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L and O'Shaughnessy J: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 26: 3950-3957, 2008.
23. Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P and Kalofonos HP: A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2008 (in press).
24. Boccia RV, Vaughn L, Zeigler H, Wang Y, Gill J, Melemed A and Shonukan O: Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial. J Clin Oncol 25(S18): 43s (abstract 1046), 2007.
25. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, Brors B, Rudlowski C, Benner A, Schuetz F, Tews B, Eils R, Sinn HP, Sohn C and Lichter P: Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24: 1839-1845, 2006. (Pubitemid 46638981)
26. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H and O'Connell P: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23: 1169-1177, 2005. (Pubitemid 46202273)
27. Iwao-Koizumi K, Matoba R, Ueno N, Jin Kim S, Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431, 2005. (Pubitemid 46224217)